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ABSTRACT:
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin 
(mTOR) axis regulates essential cellular functions including cell survival, proliferation, 
metabolism, migration, and angiogenesis. The PI3K pathway is activated in human 
cancers  by  mutation,  amplification,  and  deletion  of  genes  encoding  components 
of this pathway. The critical role of PI3K in cancer has led to the development of 
drugs targeting the effector mechanisms of this signaling network. Recent studies 
have shown that inhibition at multiple levels of the PI3K pathway results in FOXO-
dependent feedback reactivation of several receptor tyrosine kinases (RTKs) 
which, in turn, limit the sustained inhibition of this pathway and attenuates the 
action of therapeutic antagonists. This suggests that if used as single agents, PI3K 
pathway inhibitors may have limited clinical activity. We propose herein that to 
successfully target the output of the PI3K pathway in cancer cells, combination 
therapies that hinder these compensatory mechanisms should be used. Thus, 
combination therapies that target RTKs, PI3K, and mTOR activities may be required 
to  maximize  the  clinical  benefit  derived  from  treatment  with  these  inhibitors.
INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K) pathway 
is an important regulator in cell survival, proliferation, and 
apoptosis. PI3K is a major signaling hub downstream of 
HER2 and other receptor tyrosine kinases (RTKs). PI3K 
activates AKT, SGK, PDK1, mTOR, and several other 
molecules involved in cell cycle progression and survival. 
The PI3K pathway is one of the most frequently altered 
networks in cancer [1], with mutation and/or amplification 
of the genes encoding RTKs such as HER2 (ERBB2) and 
FGFR1, the PI3K catalytic subunits p110α (PIK3CA) 
and p110β (PIK3CB), the PI3K regulatory subunit p85α 
(PIK3R1), the PI3K activator mutant K-RAS, the PI3K 
effectors AKT1, AKT2, PDK1, and loss of the lipid 
phosphatases PTEN and INPP4B. PI3K is activated by 
growth factor RTKs and G-protein-coupled receptors 
(GPCRs). PI3K phosphorylates phosphatidylinositol 
4,5-bisphosphate (PIP2) to produce the second messenger 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) [2, 3]. 
Upon formation of PIP3, the pleckstrin homology (PH) 
domain of AKT and PDK1 colocalize at the plasma 
membrane, resulting in phosphorylation at T308 and 
activation of AKT. Negative regulation of this pathway 
is conferred by PTEN and INPP4B, which cleave a 
phosphate group in PIP3 and PIP2, respectively. AKT 
activates the mTOR-containing complex 1 (TORC1) 
which, via S6K and 4E-BP1, regulates mRNA translation 
and protein synthesis. mTOR is part of another complex 
(TORC2), which phosphorlylates AKT at S473 and fully 
induces its catalytic activity. Little is known about the 
upstream activators of TORC2 although it is generally 
thought that growth factors, directly or indirectly, control 
its activity. 
Class  IA  PI3K  isoforms  (PIK3Cα,  PIK3Cβ,  and 
PIK3Cδ) are heterodimeric proteins that contain a p110 
catalytic subunit and a p85 regulatory subunit. Three genes, 
PIK3CA, PIK3CB, and PIK3CD, encode the homologous 
p110α, p110β, and p110δ isozymes, respectively. p110α 
and p110β are ubiquitously expressed whereas p110δ is Oncotarget 2011; 2:   1314 - 1321 1315 www.impactjournals.com/oncotarget
largely limited to immune and hematopoietic cells. The 
p110α isozyme is necessary for growth of tumors driven 
by RTKs, mutant Ras, and/or PIK3CA mutations [4]. 
Conversely, p110β lies downstream of GPCR signaling 
and ablation of p110β, but not that of p110α, impedes 
tumorigenesis  in  PTEN-deficient  cells  [5].  PIK3CA 
mutations are the most common genetic alterations of this 
pathway in breast cancer, where ≥80% occur within “hot 
spots” of exons 9 and 20, corresponding to the helical 
(E542K and E545K) and kinase (H1047R) domains 
of p110α. These mutations result in an enzyme with 
increased catalytic activity through unique mechanisms 
[6], but both induce similar features of transformation 
including growth factor- and anchorage-independent 
growth, and protection from anoikis [7]. 
The PI3K pathway and its upstream and downstream 
effectors include many potential targets for drug 
development in cancer. Drugs inhibiting this pathway 
at different levels used alone or in combination with 
chemotherapy, radiation, or other targeted therapies are 
being evaluated in preclinical and clinical trials and have 
been summarized recently [8, 9]
INHIBITION OF THE P13K PATHWAY 
RESULTS IN FEEDBACK REACTIVATION 
OF MULTIPLE RTKS
Negative feedback regulation at different levels in 
the PI3K pathway has been well-documented [10-12]. 
These feedback loops may have evolved in multicellular 
organisms to manage growth and nutrient use by 
individual cells with that of the whole organism [13]. One 
of the first indications of negative-feedback regulation of 
the pathway in cancer was found with rapamycin. The 
macrolide rapamycin and its analogs (rapalogs) complex 
with FK506-binding protein (FKBP12); this complex then 
binds to mTOR and, as a result, inhibits the kinase activity 
of TORC1 but not TORC2. Inhibition of TORC1 and 
downstream S6K with the rapalog everolimus derepresses 
levels of insulin receptor substrate (IRS)-1 expression 
leading to activation of PI3K and phosphorylation of 
AKT at S473 in both cancer cell lines and tumors of 
patients [14-16]. These findings may explain the limited 
clinical activity of TORC1 inhibitors when used as 
single agents. This observation led to a phase I study of 
a TORC1 inhibitor and an IGF-IR neutralizing antibody. 
The combination of both drugs showed interesting clinical 
activity in patients with luminal B metastatic breast cancer 
[17]. Inhibition of mTORC1 was also shown to activate the 
MAPK pathway [18]. In a study of patients treated with 
the TORC1 inhibitor everolimus, tumors exhibited strong 
upregulation of ERK phosphorylation. This feedback loop 
was shown to depend on an S6K-PI3K-Ras pathway. 
One approach to circumvent the feedback caused by 
rapalogs is use of compounds that target the ATP-binding 
cleft of mTOR and are thus active against both TORC1 and 
TORC2. Rodrik-Outmezguine et al. recently reported that 
inhibition of TORC1/2 with the small molecule AZD8055 
resulted in dephosphorylation of AKT at S473 and a rapid 
but only transient inhibition of T308 P-AKT. Inhibition 
of TORC1/2 also relieved feedback inhibition of RTKs 
resulting in formation of PIP3 and rephosphorylation 
of AKT at T308. Upon recovery of T308 P-AKT, 
multiple AKT substrates, including FoxO, regained 
phosphorylation, suggesting T308 P-AKT is catalytically 
competent. This reinduction of T308 P-AKT and AKT 
substrates was sensitive to inhibition of AKT but not 
readdition of mTOR kinase inhibitors, thus demonstrating 
that such reinduction results from hyperactivity of PI3K. 
Finally, combined inhibition of mTOR kinase (TORC1/2) 
and RTKs prevented the rebound of T308 P-AKT and 
resulted in enhanced cell death and tumor regressions in 
vivo [19]. 
Similar to the report using TORC1/2 inhibitors, 
Chandarlapaty and colleagues showed that blockade of 
AKT (upstream of TORC1 and downstream of TORC2) 
with an allosteric kinase inhibitor also resulted in 
enhanced transcription and phosphorylation of multiple 
RTKs including HER3, IGF-1R, and insulin receptor 
[20]. These changes are the result of both inhibition of 
TORC1 and also derepression of FOXO-dependent 
transcription. Like for rapalogs, inhibition at the level of 
p110 also results in a compensatory activation of ERK 
signaling [21]. The activation of HER (ErbB) receptors, 
as indicated by increased expression of HER3 and binding 
of adaptor molecules to phosphorylated HER2-HER3 
dimers, collectively result in enhanced ERK signaling. 
The combination of PI3K inhibitors with either HER2 
or MEK inhibitors resulted in decreased proliferation, 
enhanced cell death and superior anti-tumor activity in 
vivo compared with single agent PI3K inhibitors.
INHIBITION OF P13K IS INCOMPLETE 
WITH SINIGLE AGENTS
Cancer cells that depend on the HER2 oncogene 
rely heavily of PI3K activity [22, 23]. In these cells, PI3K 
is activated by phosphorylated HER2-HER3 dimers. 
Knockdown of HER3, the adaptor that directly binds PI3K 
(p85) in these cells, inhibits PI3K and viability of HER2-
dependent breast cancer cells [24]. In a clinical trial where 
patients with HER2+ breast cancer were treated with the 
HER2 TKI lapatinib, there was significant upregulation of 
HER3 protein without inhibition of S473-AKT in tumor 
core biopsies obtained at 2 weeks of treatment [25, 26]. 
This result was somewhat surprising as tumors were 
shrinking during therapy with the single agent TKI. The 
rebound of HER3 protein levels was secondary to the 
initial inhibition of PI3K-AKT and derepression of FoxO-
mediated HER3 mRNA transcription. Recovery of HER3 
phosphorylation was secondary to residual HER2 kinase 
activity and maintenance of ligand-independent HER2-Oncotarget 2011; 2:   1314 - 1321 1316 www.impactjournals.com/oncotarget
HER3 dimers. Inhibition of HER3 with either siRNA or 
a neutralizing receptor antibody sensitized to lapatinib, 
providing evidence that the upregulation of HER3 mRNA 
and rebound phosphorylation of the HER3 RTK were 
counteracting the full effect of lapatinib [25].  
The data summarized above suggest that single 
agent HER2 inhibitors cannot block completely the 
signaling output from HER2 to HER3-PI3K-AKT. They 
also suggest that surrogate markers of PI3K activity 
would be valuable metrics to assess the magnitude of 
therapeutic pharmacodynamic inhibition in tumors that 
depend on oncogenes that activate and depend on PI3K. 
Genes encoding most glycolytic enzymes are under 
dominant transcriptional control by PI3K/AKT [27]. 
Further, activation of AKT stimulates glucose import and 
metabolism [28]. Thus, a rapid decrease in [18F]-fluoro-
deoxyglucose positron emission tomography (FDG-PET) 
uptake may represent a surrogate marker of inactivation 
of the PI3K/AKT pathway. In a recent study, we treated 
HER2+ BT474 xenografts with the combination of 
lapatinib and U3-1287, a neutralizing HER3 monoclonal 
antibody [29, 30]. To determine whether the combined 
inhibition of HER2 and HER3 with lapatinib and U3-
1287 improved the inhibition of PI3K over each single 
agent, we used FDG-PET imaging. Baseline tumor [18F]
FDG uptake was measured; mice were then randomized 
to control vehicle, lapatinib, U3-1287, or both drugs 
combined and re-imaged on day 14. Treatment with the 
combination resulted in a statistically significant decrease 
in [18F]FDG tumor uptake compared to both vehicle- and 
lapatinib-treated mice (Figure 1A and B). Treatment with 
U3-1287 alone had no effect on [18F]FDG uptake (data not 
shown). At 14 days of therapy there was no statistically 
difference in tumor volume for any of the treatment groups 
[25], suggesting that [18F]FDG uptake can be used as an 
early imaging biomarker predictive of response to a PI3K 
inhibitory therapy. Immunoblot analysis of tumor lysates 
from tumors harvested at 28 days of treatment revealed 
greater inhibition of P-AKT and P-Erk in xenografts 
treated with the combination compared to xenografts 
treated with lapatinib alone (Figure 1C). After 4 weeks of 
therapy, tumors treated with the combination exhibited a 
markedly reduced volume compared to the lapatinib and 
control arms [25]. These results suggest that a single-agent 
inhibitor is ineffective at completely blocking the PI3K 
pathway and that combination approaches are needed 
to block feedback-regulated pathways thus completing 
blockade of the PI3K axis.
In a second example, we reported that treatment with 
the pan-PI3K inhibitor XL-147 (Exelixis) was followed 
by up-regulation of expression and phosphorylation of 
several RTKs, including HER3, InsR, IGF-1R, FGFR2/3 
[31]. Knockdown of FoxO1 and FoxO3a transcription 
factors suppressed the induction of HER3, InsR, IGF-1R, 
Figure 1: Inhibition of HER3 sensitizes cells to the HER2 inhibitor lapatinib in vivo. Female athymic mice were injected with 
BT474 cells as described [25]. Once tumors reached a volume ≥250 mm3, mice were randomized to 1) 20 mg/kg normal human IgG i.p. 
twice a week and vehicle daily via orogastric gavage (control), 2) lapatinib (100 mg/kg daily via orogastric gavage), 3) U3-1287 (20 mg/
kg i.p. twice a week), or 4) a combination of lapatinib and U3-1287. Treatment was administered for 4 weeks. (A,B). Tumor-bearing mice 
were imaged at baseline for [18F]FDG uptake, treated as described above and re-imaged on day 14 (n=8-11 per group). (A). Images from a 
representative mouse show [18F]FDG uptake pre- and post-treatment. (B). top: Plot of the % change in [18F]FDG uptake at day 14 compared 
to baseline is shown. (B). bottom: Raw values of [18F]FDG %ID/g at 14 days post-treatment. Boxes indicate 25th to 75th percentile of values. 
The solid line indicates the median value and external lines show the complete range. (C). At the end of 4 weeks of treatment, mice were 
sacrificed either 1 or 24 h after the last dose of lapatinib. Tumor cell lysates were prepared and separated in a 7% SDS gel followed by 
immunoblot analysis with the indicated antibodies. Oncotarget 2011; 2:   1314 - 1321 1317 www.impactjournals.com/oncotarget
and FGFR2 mRNAs upon inhibition of PI3K. In HER2+ 
cells, HER3 was the main RTK that became reactivated 
upon treatment with XL-147. Further, addition of 
lapatinib or the HER2 antibody trastuzumab to XL-147 in 
mice with established BT474 xenografts resulted in better 
growth inhibition as well as reduction of tumor levels of 
P-HER3, P-AKT, and P-S6. 
T the biologically relevant RTKs that compensate for 
inhibition of PI3K-AKT in cancers expressing low levels 
of HER2 are less clear. We have examined this question 
in ER+/HER2-negative MCF7 human breast cancer 
cells which also harbor an activating E545K mutation in 
PIK3CA (p110α) [32]. In these cells, treatment with the 
pan-PI3K inhibitor BKM120 [33] over a time-course was 
followed by upregulation of total and phosphorylated InsR 
at 24 h (Figure 2A,B). The compensatory upregulation 
of total and P-InsR upon inhibition of PI3K suggested 
that combined inhibition of InsR and PI3K would 
synergistically inhibit tumor cell viability. Therefore, we 
transfected MCF7 cells with InsR siRNA oligonucleotides 
in combination with BKM120. The combination of InsR 
knockdown and BKM120 resulted in a statistical reduction 
in cell growth compared to either treatment alone. This was 
further confirmed by immunoblot of PARP, a biomarker 
of cell death (Figure 2C). These data further suggest that 
upon inhibition of PI3K, PI3K-dependent cells upregulate 
RTKs that hamper the efficacy of a single-agent PI3K 
pathway inhibitor. Taken together, the findings presented 
here and elsewhere [14, 18-21, 25, 31] reveal a complex 
network of feedback regulation between PI3K, mTOR, 
and RTKs.
CLINICAL IMPLICATIONS
These  findings  have  obvious  translational 
implications for the treatment of PI3K-pathway dependent 
cancers. The relief of negative feedback loops upon 
inhibition of different levels in the PI3K-AKT pathway 
and subsequent reactivation of RTKs suggest that, if used 
as single agents, PI3K inhibitors will have suboptimal 
clinical activity. It is possible that relief of these feedback 
A
B
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Figure 2: PI3K inhibition in MCF7 cells results in compensatory upregulation of InsR. (A). MCF7 cells were treated with 
1 µM BKM120 for the indicated time points; at these times cells were harvested and cell lysates prepared. Cell lysates (500 µg) were 
hybridized with phospho-RTK arrays (R&D Systems) according to the manufacturer’s instructions. (B). Fifty µg/lane of cell lysate from 
A were separated by SDS-PAGE followed by transfer to nitrocellulose and immunoblot analysis with the indicated antibodies. (C). MCF7 
cells were transfected with 50 nM of control or InsR siRNA and seeded in 6-well plates followed by treatment with 1 µM BKM120. Seven 
days after transfection, the cells were harvested and counted in a Coulter counter (top panel). Three days post-transfection (or 24 h after 
treatment with BKM120) cell lysates were prepared and subjected to immunoblot analyses for InsR, PARP, and Actin (control; bottom 
panel). Each bar represents mean ± SE cell number in triplicate wells (*p<0.05). Oncotarget 2011; 2:   1314 - 1321 1318 www.impactjournals.com/oncotarget
loops is also occurring in non-tumor host tissues and thus 
ameliorating drug-related toxicities. Combined targeting 
of different levels of the PI3K pathway, i.e., TORC1/2 and 
p110, RTK and p110; RTK and TORC1/2, etc., in order to 
more completely suppress its signaling output, have not 
been fully explored. Whether those combined approaches 
limit feedback reactivation and, as a result, block the 
pathway more strongly and/or whether they are clinically 
well tolerated and feasible remains to be determined. 
Compensatory feedback may not be limited to RTKs. 
For example, inhibition of PI3K in prostate cancer cells 
activates signaling by the androgen receptor (AR) and 
inhibition of the AR, in turn, activates AKT signaling 
by reducing levels of the AKT phosphatase PHLPP [34]. 
Whether similar coordinate regulation of steroid receptors 
exists in other hormone-dependent tumors remains to 
be established. Interestingly, however, experimental and 
clinical evidence suggests that hyperactivation of the PI3K 
pathway promotes antiestrogen resistance in breast cancer 
[35], suggesting that simultaneous targeting of PI3K and 
ER pathways may be effective in ER+ breast cancer [36]. 
The ability of these combinations to perform in the clinic 
is currently the focus of active investigation. Ideally, these 
studies should confirm whether the feedback reactivation 
seen in the laboratory in cancer cells following PI3K-
AKT inhibition is of the same nature in primary tumors. 
INHIBITION OF P13K IS INCOMPLETE 
WITH SINGLE AGENTS
Cancer cells that depend on the HER2 oncogene 
rely heavily of PI3K activity [22, 23]. In these cells, PI3K 
is activated by phosphorylated HER2-HER3 dimers. 
Knockdown of HER3, the adaptor that directly binds PI3K 
(p85) in these cells, inhibits PI3K and viability of HER2-
dependent breast cancer cells [24]. In a clinical trial where 
patients with HER2+ breast cancer were treated with the 
HER2 TKI lapatinib, there was significant upregulation of 
HER3 protein without inhibition of S473-AKT in tumor 
core biopsies obtained at 2 weeks of treatment [25, 26]. 
This result was somewhat surprising as tumors were 
shrinking during therapy with the single agent TKI. The 
rebound of HER3 protein levels was secondary to the 
initial inhibition of PI3K-AKT and derepression of FoxO-
mediated HER3 mRNA transcription. Recovery of HER3 
phosphorylation was secondary to residual HER2 kinase 
activity and maintenance of ligand-independent HER2-
HER3 dimers. Inhibition of HER3 with either siRNA or 
a neutralizing receptor antibody sensitized to lapatinib, 
providing evidence that the upregulation of HER3 mRNA 
and rebound phosphorylation of the HER3 RTK were 
counteracting the full effect of lapatinib [25].  
The data summarized above suggest that single 
agent HER2 inhibitors cannot block completely the 
signaling output from HER2 to HER3-PI3K-AKT. They 
also suggest that surrogate markers of PI3K activity 
would be valuable metrics to assess the magnitude of 
therapeutic pharmacodynamic inhibition in tumors that 
depend on oncogenes that activate and depend on PI3K. 
Genes encoding most glycolytic enzymes are under 
dominant transcriptional control by PI3K/AKT [27]. 
Further, activation of AKT stimulates glucose import and 
metabolism [28]. Thus, a rapid decrease in [18F]-fluoro-
deoxyglucose positron emission tomography (FDG-PET) 
uptake may represent a surrogate marker of inactivation 
of the PI3K/AKT pathway. In a recent study, we treated 
HER2+ BT474 xenografts with the combination of 
lapatinib and U3-1287, a neutralizing HER3 monoclonal 
antibody [29, 30]. To determine whether the combined 
inhibition of HER2 and HER3 with lapatinib and U3-
1287 improved the inhibition of PI3K over each single 
agent, we used FDG-PET imaging. Baseline tumor [18F]
FDG uptake was measured; mice were then randomized 
to control vehicle, lapatinib, U3-1287, or both drugs 
combined and re-imaged on day 14. Treatment with the 
combination resulted in a statistically significant decrease 
in [18F]FDG tumor uptake compared to both vehicle- and 
lapatinib-treated mice (Figure 1A and B). Treatment with 
U3-1287 alone had no effect on [18F]FDG uptake (data not 
shown). At 14 days of therapy there was no statistically 
difference in tumor volume for any of the treatment groups 
[25], suggesting that [18F]FDG uptake can be used as an 
early imaging biomarker predictive of response to a PI3K 
inhibitory therapy. Immunoblot analysis of tumor lysates 
from tumors harvested at 28 days of treatment revealed 
greater inhibition of P-AKT and P-Erk in xenografts 
treated with the combination compared to xenografts 
treated with lapatinib alone (Figure 1C). After 4 weeks of 
therapy, tumors treated with the combination exhibited a 
markedly reduced volume compared to the lapatinib and 
control arms [25]. These results suggest that a single-agent 
inhibitor is ineffective at completely blocking the PI3K 
pathway and that combination approaches are needed 
to block feedback-regulated pathways thus completing 
blockade of the PI3K axis.
In a second example, we reported that treatment with 
the pan-PI3K inhibitor XL-147 (Exelixis) was followed 
by up-regulation of expression and phosphorylation of 
several RTKs, including HER3, InsR, IGF-1R, FGFR2/3 
[31]. Knockdown of FoxO1 and FoxO3a transcription 
factors suppressed the induction of HER3, InsR, IGF-1R, 
and FGFR2 mRNAs upon inhibition of PI3K. In HER2+ 
cells, HER3 was the main RTK that became reactivated 
upon treatment with XL-147. Further, addition of 
lapatinib or the HER2 antibody trastuzumab to XL-147 in 
mice with established BT474 xenografts resulted in better 
growth inhibition as well as reduction of tumor levels of 
P-HER3, P-AKT, and P-S6. 
T the biologically relevant RTKs that compensate for 
inhibition of PI3K-AKT in cancers expressing low levels 
of HER2 are less clear. We have examined this question 
in ER+/HER2-negative MCF7 human breast cancer Oncotarget 2011; 2:   1314 - 1321 1319 www.impactjournals.com/oncotarget
cells which also harbor an activating E545K mutation in 
PIK3CA (p110α) [32]. In these cells, treatment with the 
pan-PI3K inhibitor BKM120 [33] over a time-course was 
followed by upregulation of total and phosphorylated InsR 
at 24 h (Figure 2A,B). The compensatory upregulation 
of total and P-InsR upon inhibition of PI3K suggested 
that combined inhibition of InsR and PI3K would 
synergistically inhibit tumor cell viability. Therefore, we 
transfected MCF7 cells with InsR siRNA oligonucleotides 
in combination with BKM120. The combination of InsR 
knockdown and BKM120 resulted in a statistical reduction 
in cell growth compared to either treatment alone. This was 
further confirmed by immunoblot of PARP, a biomarker 
of cell death (Figure 2C). These data further suggest that 
upon inhibition of PI3K, PI3K-dependent cells upregulate 
RTKs that hamper the efficacy of a single-agent PI3K 
pathway inhibitor. Taken together, the findings presented 
here and elsewhere [14, 18-21, 25, 31] reveal a complex 
network of feedback regulation between PI3K, mTOR, 
and RTKs.
CLINICAL IMPLICATIONS
These  findings  have  obvious  translational 
implications for the treatment of PI3K-pathway dependent 
cancers. The relief of negative feedback loops upon 
inhibition of different levels in the PI3K-AKT pathway 
and subsequent reactivation of RTKs suggest that, if used 
as single agents, PI3K inhibitors will have suboptimal 
clinical activity. It is possible that relief of these feedback 
loops is also occurring in non-tumor host tissues and thus 
ameliorating drug-related toxicities. Combined targeting 
of different levels of the PI3K pathway, i.e., TORC1/2 and 
p110, RTK and p110; RTK and TORC1/2, etc., in order to 
more completely suppress its signaling output, have not 
been fully explored. Whether those combined approaches 
limit feedback reactivation and, as a result, block the 
pathway more strongly and/or whether they are clinically 
well tolerated and feasible remains to be determined. 
Compensatory feedback may not be limited to RTKs. 
For example, inhibition of PI3K in prostate cancer cells 
activates signaling by the androgen receptor (AR) and 
inhibition of the AR, in turn, activates AKT signaling 
by reducing levels of the AKT phosphatase PHLPP [34]. 
Whether similar coordinate regulation of steroid receptors 
exists in other hormone-dependent tumors remains to 
be established. Interestingly, however, experimental and 
clinical evidence suggests that hyperactivation of the PI3K 
pathway promotes antiestrogen resistance in breast cancer 
[35], suggesting that simultaneous targeting of PI3K and 
ER pathways may be effective in ER+ breast cancer [36]. 
The ability of these combinations to perform in the clinic 
is currently the focus of active investigation. Ideally, these 
studies should confirm whether the feedback reactivation 
seen in the laboratory in cancer cells following PI3K-
AKT inhibition is of the same nature in primary tumors. 
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